Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
0.0360
+0.0010
+2.86%
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Navidea Biopharmaceuticals Inc (NAVB)
Add to/Remove from a Portfolio
Add to Watchlist
- Volume: 9,441
- Bid/Ask: 0.0000 / 0.0000
- Day's Range: 0.0300 - 0.0455
Type:
Equity
Market:
United States
Navidea Biopharma
0.0360
+0.0010
+2.86%
- Discussions
- Recent Sentiments
- User Rankings
NAVB User Rankings
Bellow, users are ranked according to the performance of their sentiments for the Navidea Biopharmaceuticals Inc stock.
| Rank | Username | Total | Closed | Winning | Win % | Chg. % |
|---|---|---|---|---|---|---|
| 1 | Hermann Albrecht | 3 | 3 | 3 | 100 | +1727.55% |
| 2 | CJ Miller | 3 | 3 | 3 | 100 | +326.27% |
| 3 | James Odulio | 1 | 1 | 1 | 100 | +196.5% |
| 4 | Tony Nguyen | 1 | 1 | 1 | 100 | +196.5% |
| 5 | Omar Etrata | 1 | 1 | 1 | 100 | +174.6% |
| 6 | Robbert Kuipers | 1 | 1 | 1 | 100 | +121.7% |
| 7 | Cesar Irizarry | 1 | 1 | 1 | 100 | +89.53% |
| 8 | FREDRICK Gray | 1 | 1 | 1 | 100 | +82.38% |
| 9 | Carlos Wicks | 1 | 1 | 1 | 100 | +82.38% |
| 10 | manohar Boddu | 1 | 1 | 1 | 100 | +75.75% |
| 11 | davide garulli | 2 | 2 | 2 | 100 | +72.64% |
| 12 | דוד לסקר | 1 | 1 | 1 | 100 | +55.9% |
| 13 | CTaylor TaylorMade | 1 | 1 | 1 | 100 | +46.9% |
| 14 | Jordan Anger | 1 | 1 | 1 | 100 | +42.57% |
| 15 | Sheikh Shawan | 1 | 1 | 1 | 100 | +38.48% |
| 16 | Thin Blue | 1 | 1 | 1 | 100 | +38.46% |
| 17 | Sadiq Abdulla | 1 | 1 | 1 | 100 | +35.59% |
| 18 | NICOLA ESPOSITO | 9 | 9 | 3 | 33.33 | +27.68% |
| 19 | Chew Hau | 1 | 1 | 1 | 100 | +25.87% |
| 20 | samu urendes | 1 | 1 | 1 | 100 | +25.24% |
| 21 | Adi Horn | 1 | 1 | 1 | 100 | +11.68% |
| 22 | Jeremy Colbert | 1 | 1 | 1 | 100 | +10.45% |
| 23 | Jimmy Varriano | 1 | 1 | 1 | 100 | +4.65% |
| 24 | Guillaume Côté | 1 | 1 | 1 | 100 | +2.7% |
| 25 | Michael Attias | 1 | 1 | 1 | 100 | +2.17% |
| 26 | Daniel Rodriguez | 1 | 1 | 1 | 100 | +2.17% |
| 27 | Freddie Crawford | 1 | 1 | 0 | 0 | 0% |
| 28 | Alejandro Enríquez | 1 | 1 | 0 | 0 | 0% |
| 29 | Roxanne Seon | 1 | 1 | 0 | 0 | 0% |
| 30 | Евгений Пестряев | 1 | 1 | 0 | 0 | -1.89% |
| 31 | Rhys Hemert | 1 | 1 | 0 | 0 | -1.89% |
| 32 | Santi Vila Turon | 2 | 2 | 1 | 50 | -2.48% |
| 33 | ???? ????? | 1 | 1 | 0 | 0 | -2.6% |
| 34 | Jim Badrow | 1 | 1 | 0 | 0 | -2.7% |
| 35 | Florin .. | 1 | 1 | 0 | 0 | -2.96% |
| 36 | Madhavi Reddy | 1 | 1 | 0 | 0 | -5.53% |
| 37 | Ricardo Tanur | 1 | 1 | 0 | 0 | -7.07% |
| 38 | yai banlao | 1 | 1 | 0 | 0 | -14.92% |
| 39 | Jorge Miguel Antunes | 1 | 1 | 0 | 0 | -15.78% |
| 40 | Rafat Nadi | 1 | 1 | 0 | 0 | -17.42% |
| 41 | Roberto Albertini | 1 | 1 | 0 | 0 | -21.1% |
| 42 | Владимир Бобачев | 1 | 1 | 0 | 0 | -23.06% |
| 43 | Jorge Rodriguez | 1 | 1 | 0 | 0 | -23.21% |
| 44 | אברהם גולד | 2 | 2 | 0 | 0 | -31.27% |
| 45 | phuk QQ | 1 | 1 | 0 | 0 | -34.15% |
| 46 | Robbert Kuipers | 1 | 1 | 0 | 0 | -34.86% |
| 47 | ahmad iraqui | 1 | 1 | 0 | 0 | -37.97% |
| 48 | Gerrit Bijster | 1 | 1 | 0 | 0 | -38.69% |
| 49 | 케이 딕 | 1 | 1 | 0 | 0 | -39.44% |
| 50 | יעקב ענמואל | 1 | 1 | 0 | 0 | -48.18% |
Write your thoughts about Navidea Biopharmaceuticals Inc
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Tyler Philipation
May 24, 2023 16:45
can you say after hour stock manipulation!
0
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review